Peptides for Burns: Accelerating Skin Regeneration
Peptide Wound Healing
42% faster reepithelialization
Thymosin beta-4 increased wound reepithelialization by 42% at 4 days and up to 61% at 7 days compared to saline controls in a rat full-thickness wound model.
Kamil et al., EXCLI Journal, 2025
Kamil et al., EXCLI Journal, 2025
View as imageBurns are among the most complex wounds the body faces. Unlike a clean surgical incision, a burn destroys multiple tissue layers simultaneously, triggers a massive inflammatory cascade, creates a wound bed vulnerable to infection, and often produces scarring that limits function for years. An estimated 11 million people worldwide require medical treatment for burns annually, and deep burns that exceed the skin's capacity for self-repair remain a major clinical challenge. Several peptide classes have shown the ability to accelerate burn healing in animal models by targeting specific phases of the repair process: dampening excessive inflammation, stimulating new blood vessel formation, promoting cell migration into the wound bed, and remodeling scar tissue. For a broader view of how peptides fit into wound care, see our pillar article on peptide-based wound dressings.
Key Takeaways
- BPC-157 cream applied to 20% body surface area burns in mice decreased inflammatory cell infiltration and increased skin breaking strength at 7 and 14 days (Mikus et al., Burns, 2001)
- BPC-157 enhanced alkali-burn wound closure to 95% by day 12 vs 65% in controls, driven by increased angiogenesis and cell migration (Huang et al., Drug Design Dev Ther, 2015)
- Growth hormone-releasing hormone agonist JI-34 accelerated wound closure by 50% in rats through upregulation of VEGF and TGF-beta (Dioufa et al., PNAS, 2010)
- GHK-Cu modulates over 4,000 gene expressions related to tissue repair, including upregulation of collagen types I and III and downregulation of metalloproteinases (Pickart et al., BioMed Research International, 2015)
- Dual-function antimicrobial-wound healing peptides kill bacteria while simultaneously promoting keratinocyte migration (de Barros et al., Peptides, 2022)
- A comprehensive 2025 review identified peptide hydrogels as the most promising delivery platform for burn wound applications (Kamil et al., EXCLI Journal, 2025)
Why burns heal differently from other wounds
Burn injuries create a wound environment fundamentally different from cuts, abrasions, or surgical incisions. The initial thermal damage triggers a zone of coagulative necrosis surrounded by a zone of stasis, where cells are injured but potentially salvageable. Whether those cells survive or die determines the final depth of the burn. Excessive inflammation in the first 48 hours can convert the zone of stasis into additional necrosis, deepening the wound.[1]
This progression creates specific targets for peptide intervention. Peptides that reduce early inflammatory damage can prevent wound deepening. Peptides that promote angiogenesis restore blood supply to the injured tissue. Peptides that accelerate keratinocyte and fibroblast migration speed wound closure. The challenge is timing: different peptides are needed at different phases of healing, and delivering them to a damaged, often infected wound bed adds practical complexity.
BPC-157: the gastric peptide in burn research
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide originally isolated as a fragment of a protein found in human gastric juice. Its investigation in burn wounds began with a 2001 study by Mikus et al. that remains the most direct evidence for peptide-mediated burn healing improvement.[2]
In that study, deep partial-thickness burns covering 20% of total body surface area were induced in mice. BPC-157 was applied topically as a cream (50 micrograms dissolved in 2 ml of water mixed with 50 grams of neutral cream) and also tested via intraperitoneal injection. Both routes produced measurable improvements: decreased inflammatory cell infiltration in the burn wound, reduced water content in burned skin (indicating less edema), and increased breaking strength during tensiometry at 7 and 14 days post-burn. The peptide also attenuated the gastric lesions that commonly develop after severe burns, a dual protective effect consistent with BPC-157's gastric origin.[2] For a deeper look at this peptide's angiogenic mechanism, see our article on how BPC-157 promotes angiogenesis.
Huang et al. extended this work in 2015 using an alkali-burn model rather than thermal burns. BPC-157 treatment accelerated wound closure to approximately 95% by day 12, compared to 65% in untreated controls. The mechanism involved increased proliferation and migration of dermal fibroblasts, enhanced angiogenesis (measured by CD31-positive vessel density), and upregulation of VEGF expression in the wound bed. In vitro tube formation assays confirmed that BPC-157 directly promoted endothelial cell organization into vascular structures.[3]
Both studies are animal research. BPC-157 has not been tested in human burn patients in any published clinical trial. The peptide's clinical development for any indication has been slow despite decades of preclinical work. For context on the broader evidence landscape for this peptide, see BPC-157: what the research shows.
GHK-Cu: the copper peptide and skin remodeling
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. Plasma concentrations decline from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60, a decline that correlates with reduced wound healing capacity.[4]
Pickart et al.'s comprehensive 2015 review documented that GHK-Cu modulates over 4,000 gene expressions relevant to tissue repair. The peptide upregulates collagen types I, III, and V, promotes synthesis of proteoglycans and glycosaminoglycans that form the wound extracellular matrix, and simultaneously downregulates matrix metalloproteinases that break down newly formed tissue. This balance between synthesis and controlled remodeling is particularly relevant for burn healing, where excessive collagen deposition produces hypertrophic scars and contractures.[4]
In wound models, GHK-Cu has demonstrated acceleration of dermal contraction, increased tensile strength of healed skin, and improved cosmetic appearance of scars. The copper component is not merely structural; it serves as a cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin fibers, and for superoxide dismutase, which protects healing tissue from oxidative damage. For a comprehensive treatment of this peptide's wound healing properties, see GHK-Cu in wound repair.
Growth hormone-releasing hormone and wound acceleration
Growth hormone-releasing hormone (GHRH) agonists represent a different approach: rather than acting directly on the wound, they amplify the body's growth factor signaling. Dioufa et al. published a 2010 PNAS study showing that GHRH agonist JI-34 accelerated wound closure by 50% in a rat full-thickness wound model.[5]
The mechanism involved direct effects on wound cells rather than systemic growth hormone elevation. JI-34 increased expression of VEGF (vascular endothelial growth factor) and TGF-beta (transforming growth factor-beta) in wound tissue, promoted keratinocyte and fibroblast proliferation, and enhanced granulation tissue formation. GHRH receptors were identified on skin cells themselves, suggesting a local paracrine signaling pathway independent of the pituitary growth hormone axis.[5]
This finding is relevant for burn patients because severe burns trigger a hypermetabolic state with growth hormone resistance. Systemic growth hormone administration has been used in burn intensive care but carries side effects including hyperglycemia and fluid retention. GHRH agonist peptides that act locally at the wound site could potentially provide the regenerative benefits without the systemic metabolic disruption.
Antimicrobial peptides: fighting infection and healing simultaneously
Burns are uniquely vulnerable to infection. The damaged skin barrier, protein-rich wound exudate, and compromised local immunity create an environment where bacterial colonization can rapidly progress to wound sepsis, the leading cause of death in severe burn patients. Traditional antimicrobial treatments (silver sulfadiazine, topical antibiotics) control infection but do not actively promote healing. Some are cytotoxic to keratinocytes and fibroblasts at bactericidal concentrations.
Dual-function antimicrobial-wound healing peptides address both problems simultaneously. De Barros et al. reviewed this class of molecules in a 2022 Peptides article, documenting peptides that kill bacteria through membrane disruption while simultaneously promoting keratinocyte migration, fibroblast proliferation, and angiogenesis through receptor-mediated signaling.[6]
Wang et al. elucidated the wound healing mechanism of cathelicidin-DM, a frog-derived antimicrobial peptide that accelerated wound closure in a mouse model through direct promotion of keratinocyte migration via the JNK/c-Jun signaling pathway. The peptide killed both gram-positive and gram-negative bacteria at concentrations that were non-toxic to mammalian cells.[7]
Li et al. reported in 2025 that two novel milk-derived antimicrobial peptides (hLFT-68 and hLFT-90) accelerated cutaneous wound healing in mice while maintaining broad-spectrum antibacterial activity. The peptides promoted fibroblast migration and collagen deposition, with histological evidence of improved tissue architecture compared to untreated wounds.[8]
These dual-function peptides are particularly relevant for burns because they could replace the current two-step approach (antimicrobial application followed by separate wound healing agents) with a single treatment. For more on how antimicrobial peptides fit into wound management, see antimicrobial peptides in wound care.
Delivery: the practical barrier
Peptide instability in the wound environment is the primary obstacle to clinical translation. Burn wound exudate contains high concentrations of proteases that degrade peptides within minutes. The acidic, protein-rich fluid dilutes topically applied peptides away from cell-surface receptors. Temperature fluctuations in burns further accelerate peptide degradation.[1]
Several delivery strategies are being developed to overcome these challenges.
Peptide hydrogels are the most extensively studied delivery platform. Im et al. demonstrated in 2018 that a predefined-shape bioactive peptide hydrogel scaffold supported full-thickness skin regeneration in a porcine model, with the peptide maintaining bioactivity throughout the healing process. The hydrogel provided both structural support for tissue ingrowth and sustained peptide release over 14 days.[9]
Electrospun nanofiber scaffolds loaded with thymosin beta-4 achieved sustained release over 21 days while maintaining peptide bioactivity, according to Wu et al. (2020). The PLGA/PLA hybrid yarns protected the peptide from proteolytic degradation and provided a physical template for cell migration.[10]
Kamil et al.'s comprehensive 2025 review identified peptide-functionalized hydrogels as the most promising delivery platform for wound healing applications, noting that hydrogels simultaneously solve the problems of peptide stability, sustained release, moisture maintenance, and wound conformability.[1]
What remains unproven
The evidence for peptides in burn treatment is almost entirely preclinical. Several gaps limit clinical translation.
No human burn trials. No peptide (BPC-157, GHK-Cu, thymosin beta-4, or any antimicrobial-wound healing peptide) has been tested in a controlled clinical trial specifically for burn wound healing. The animal data is promising but burns in mice and rats differ from human burns in depth, immune response, scarring patterns, and healing timelines.
Dose and timing are unknown. Animal studies use widely varying doses, delivery methods, and treatment schedules. The optimal concentration, frequency of application, and treatment window for human burns have not been established for any peptide.
Scarring outcomes are poorly studied. Most animal wound studies measure wound closure rate and basic histology. Few measure the quality of healed tissue in terms that matter for burn patients: scar elasticity, pigmentation, contracture formation, and long-term cosmetic outcome. Burn scar research, including the complex neurobiology of scar pain, is an active field with few peptide-specific data points.[11]
Infection interaction is undertested. Most wound healing studies use clean, uninfected wounds. Burns are frequently contaminated. Whether wound healing peptides maintain their regenerative effects in infected wound beds, or whether antimicrobial peptides maintain their killing activity in burn exudate, remains poorly characterized.
Regulatory path is unclear. Peptide wound treatments would likely be regulated as biologics rather than drugs, adding development cost and complexity. The FDA pathway for combination products (peptide + delivery scaffold) adds additional regulatory burden. For insights on how peptide wound products relate to diabetic wound care, see diabetic wound healing research.
The Bottom Line
Peptides show preclinical promise for burn treatment across multiple mechanisms: BPC-157 reduces inflammation and promotes angiogenesis, GHK-Cu modulates over 4,000 genes involved in tissue remodeling, GHRH agonists accelerate wound closure by 50%, and dual-function antimicrobial peptides fight infection while promoting healing. All evidence is from animal studies. No peptide has been tested in a controlled human burn trial, and the critical challenges of delivery stability, optimal dosing, and scar quality assessment remain unresolved.